Remote Buying of Abeona Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Abeona Therapeutics Inc through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
Bank of New York Mellon Corp Increases Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) via ETF Daily News
Heron Therapeutics (NASDAQ:HRTX) Stock Crosses Below 200-Day Moving Average of $3.14 via ETF Daily News
Sarepta Therapeutics (NASDAQ:SRPT) PT Raised to $175.00 at TD Cowen via ETF Daily News
Oppenheimer Lowers Oncternal Therapeutics (NASDAQ:ONCT) Price Target to $9.00 via ETF Daily News
Roquefort Therapeutics (LON:ROQ) Shares Up 3.5% via ETF Daily News
Biora Therapeutics (NASDAQ:BIOR) Stock Price Up 4.7% via ETF Daily News
Fc Global Realty (OTCMKTS:FCRE) versus Guided Therapeutics (OTCMKTS:GTHP) Critical Analysis via ETF Daily News
Critical Survey: Albireo Pharma (NASDAQ:ALBO) & Aclaris Therapeutics (NASDAQ:ACRS) via ETF Daily News
Head-To-Head Analysis: Better Therapeutics (NASDAQ:BTTX) & DocGo (NASDAQ:DCGO) via ETF Daily News
RAPT Therapeutics (NASDAQ:RAPT) Shares Down 4.2% Following Analyst Downgrade via ETF Daily News
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company's portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical needs. Abeona's novel, next-generation AIMâ„¢ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona's fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITALâ„¢ study and is capable of clinical and commercial production of AAV-based gene therapies.
Analysis is available when the exchange & market are open.